Mark J. Mulligan, MD, is the director of the Division of Infectious Diseases & Immunology in the Department of Medicine, and director of the NYU Langone Vaccine Center. He joined NYU Langone Health in 2018. He is a translational physician-scientist who leads a research clinic and a research laboratory, conducting vaccine clinical trials and clinical studies of emerging infections. He has conducted research on HIV, Zika, Ebola, bird flu, 2009 pandemic influenza, and other vaccines and/or infections with public health impact. He is now studying the novel coronavirus. He is a graduate of the University of Notre Dame (cum laude, 1980), University of Texas Southwestern Medical School, Dallas (1984). Dr. Mulligan served as multiple PI for an NIH-funded HIV/AIDS Clinical Trials Unit, conducting AIDS and TB research in Atlanta, Kenya, the Philippines, and Thailand (2006-2018). He also served as the principal investigator for an NIH-funded Vaccine and Treatment Evaluation Unit (VTEU), 2007-18 - one of nine national units funded by NIH to conduct clinical research to combat infectious disease threats to human health. In 2020, the NYU Langone Vaccine Center received a seven-year grant from NIH/NIAID to become one of ten VTEUs currently awarded.
At the completion of this educational session, learners will:
- The learner will gain an appreciation of the progress on COVID-19 vaccines, and how the vaccine platforms compare to those being evaluated for HIV.
- Learners will understand the potential uses of MABs against SARS-CoV-2, and parallels to HIV MAB work.
- The learner will learn about COVID-19 vaccine trials in the NYC area.
- Learners will learn the latest about natural immunity to COVID-19.
This CME activity has approved for AMA PRA Category 1 Credit™
for July 22, 2020 as a live activity. This activity will also be available as an enduring activity from July 23, 2020, through July 21, 2023.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Mark J. Mulligan (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research support recipient from Lilly, and Pfizer. Dr. Mulligan will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Click here to take the CME Evaluation and Post-Meeting Evaluation